References
- Bossi G, Marampon F, Maor-Aloni R, Zani B, Rotter V, Oren M, Strano S, Blandino G, Sacchi A. 2008. Conditional RNA interference in vivo to study mutant p53 oncogenic gain of function on tumour malignancy. Cell Cycle 7:1870–1879.
- Camphausen K, Moses MA, Ménard C, Sproull M, Beecken WD, Folkman J, O’Reilly MS. 2003. Radiation abscopal antitumour effect is mediated through p53. Cancer Res 63:1990–1993.
- Cividalli A, Creton G, Ceciarelli F, Strigari L, Tirindelli Danesi D, Benassi M. 2005. Influence of time interval between surgery and radiotherapy on tumour regrowth. J Experim Clin Cancer Res 24: 109–116.
- Creton G, Benassi M, Di Staso M, Ingrosso G, Giubilei C, Strigari L. 2006. The time factor in oncology: Consequences on tumour volume and therapeutic planning. J Experim Clin Cancer Res 25:557–573.
- Demaria S, Ng B, Devitt ML, Babb JS, Kawashima N, Liebes L, Formenti SC. 2004. Ionizing radiation inhibition of distant untreated tumours (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys 58:862–870.
- Dewan MZ, Galloway AE, Kawashima N, Dewyngaert JK, Babb JS, Formenti SC, Demaria S. 2009. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res 15: 5379–5388.
- Hainaut P, Hollstein M. 2000. p53 and human cancer: The first ten thousand mutations. Adv in Cancer Res 77:81–137.
- Jaradat AK, Biggs PJ. 2008. Measurement of the neutron leakage from a dedicated intraoperative radiation therapy electron linear accelerator and a conventional linear accelerator for 9, 12, 15(16), and 18(20) MeV electron energies. Medical Phys 35:1711–1717.
- Kaminski JM, Shinohara E, Summers JB, Niermann KJ, Morimoto A, Brousal J. 2005. The controversial abscopal effect. Cancer Treat Rev 31:159–172.
- Mancuso M, Pasquali E, Leonardi S, Tanori M, Rebessi S, Di Majo V, Pazzaglia S, Toni MP, Pimpinella M, Covelli V, Saran A. 2008. Oncogenic bystander radiation effects in Patched heterozygous mouse cerebellum. Proc Nat Acad Sci USA 105:12445–12450.
- Mole RH. 1953. Whole body irradiation: Radiobiology or medicine?Br J Radiobiol 26:234–241.
- Mothersill C, Bristow RG, Harding SM, Smith RW, Mersov A, Seymour CB. 2011. A role for p53 in the response of bystander cells to receipt of medium borne signals from irradiated cells. Int J Radiat Biol 87:1120–1125.
- Ohba K, Omagari K, Nakamura T, Ikuno N, Saeki S, Matsuo I, Kinoshita H, Masuda J, Hazama H, Sakamoto I, Kohno S. 1998. Abscopal regression of hepatocellular carcinoma after radiotherapy for bone metastasis. Gut 43:575–577.
- Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, Olivier M. 2007. Impact of mutant p53 functional properties on TP53 mutation patterns and tumour phenotype: Lessons from recent developments in the IARC TP53 database. Human Mutat 28: 622–629.
- Shen L, Sun X, Fu Z, Yang G, Li J, Yao L. 2012. The fundamental role of the p53 pathway in tumour metabolism and its implication in tumour therapy. Clin Cancer Res 18:1561–1567.
- Soriani A, Felici G, Fantini M, Paolucci M, Borla O, Evangelisti G, Benassi M, Strigari L. 2010. Radiation protection measurements around a 12 MeV mobile dedicated IORT accelerator. Med Phys 37:995–1003.
- Soriani A, Landoni V, Marzi S, Iaccarino G, Saracino B, Arcangeli G, Benassi M. 2007. Setup verification and in vivo dosimetry during intraoperative radiation therapy (IORT) for prostate cancer. Med Phys 34:3205–3210.
- Strigari L, D’Andrea M, Abate A, Benassi M. 2008. A heterogeneous dose distribution in simultaneous integrated boost: The role of the clonogenic cell density on the tumour control probability. Phys Med Biol 53:5257–5273.
- Strigari L, Soriani A, Landoni V, Teodoli S, Bruzzaniti V, Benassi M. 2004. Radiation exposure of personnel during intraoperative radiotherapy (IORT): Radiation protection aspects. J Experim Clin Cancer Res 23:489–494.